Author:
Gisondi Paolo,Talamonti Marina,Chiricozzi Andrea,Piaserico Stefano,Amerio Paolo,Balato Anna,Bardazzi Federico,Calzavara Pinton Piergiacomo,Campanati Anna,Cattaneo Angelo,Dapavo Paolo,De Simone Clara,Dini Valentina,Fargnoli Maria C.,Flori Maria L.,Galluzzo Marco,Guarneri Claudio,Lasagni Claudia,Loconsole Francesco,Lo Schiavo Ada,Malagoli Piergiorgio,Malara Giovanna,Mercuri Santo R.,Musumeci Maria L.,Naldi Luigi,Papini Manuela,Parodi Aurora,Potenza Concetta,Prignano Francesca,Rongioletti Franco,Stingeni Luca,Tiberio Rossana,Venturini Marina,Bianchi Luca,Costanzo Antonio,Cusano Francesco,Girolomoni Giampiero,Offidani Anna M.,Peris Ketty
Publisher
Springer Science and Business Media LLC
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-01
2. Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps;Current Allergy and Asthma Reports;2023-12-12
3. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience;Journal of Clinical Medicine;2023-12-05
4. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-11-05
5. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial;American Journal of Clinical Dermatology;2023-10-07